Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Audentes Therapeutics  (Stock symbol: BOLD )

600 California Street, 17th Floor
San Francisco, CA 94108
USA
(415) 818-1001
Website Company Summary Management Team
Management

CEO: Matthew R. Patterson (1/31/2013)
President/COO/Operations: Natalie Holles (9/30/2015)
General Management: Mary Newman (10/1/2014) ; Michael O’Callaghan (3/4/2014) ; Barbara Wuebbels (3/4/2014) ; Jeffrey White (3/31/2015); Ted Slocomb (1/31/2015) ; Edward Connor (7/31/2019) ; Suyash Prasad (3/4/2014)
Finance: Jason Barker (2/28/2015) ; Thomas Soloway (9/30/2002)
Technology: John T. Gray (10/1/2014)
Business Development: Melita Sun Jung ; Eric B. Mosbrooker
Board

Outside board: (May no longer be on the board) Scott Morrison (Ernst & Young Former Partner) Thomas J. C. Schuetz (Dana Farber Cancer Institute Former Medical Oncology Fellow) Jonathan T. Silverstein (OrbiMed General Partner) Kush M. Parma (5AM Ventures Principal) Jonathan S. Leff (Deerfield Management Partner) Stephen Squinto (OrbiMed Venture Partner) Tom Woiwode (Versant Ventures Managing Director)
Advisory board: Bong Koh (Venrock Associates Partner)
Company

Business description: Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare muscle diseases through the application of adeno-associated virus (AAV) gene therapy technology. Audentes is dedicated to the development of innovative treatments based on adeno-associated virus (AAV) gene therapy technology. The company consists of a focused, experienced, and passionate team driven by the goal of improving the lives of patients. We take pride in strong, global relationships with the patient, research, and medical communities.
Partners include: Genethon ;  REGENX Biosciences
Capital

Rounds: 3
Recent Fundings: Oct 2015   Dec 2014
Capital raised: 137.5M
Last Round: 65.0M
Ownership: Public   Ipo Filing
Stock Symbol: BOLD
VCs include: Sofinnova Investments Venrock Associates Versant Ventures 5AM Ventures OrbiMed ;  Deerfield Management Redmile Group

Last Tweets


 

Last Mentions


Overview
Record updated: Jan 2019
Sector: Biotech
Year Founded: 2012
Headcount: 101-150 as of Jan 2019
Rounds: 3
Recent Fundings: Oct 2015   Dec 2014
Capital Raised: 137.5M
Last Round: 65.0M
Ownership: Public   Ipo Filing
Stock Symbol: BOLD